News and Events


January 23, 2017
Press Release: Omicia Acquires Bioinformatics Innovator Spiral Genetics
With Acquisition, Omicia Adds Secondary NGS Analysis and Structural Variant Capabilities

Omicia, Inc., a leading provider of clinical genomic data analysis and reporting software, announced today that it has acquired Seattle-based Spiral Genetics. Spiral’s advanced tools add multiple variant detection capabilities for next generation sequencing (NGS) to Omicia’s industry-leading software platform.

Omicia now offers a secure powerful range of NGS analysis capabilities to support high-throughput panels, exomes, and whole genomes for hereditary diseases and somatic cancer, delivering clinical reports straight into EMR workflows. Omicia’s technology has been used by more than 1,000 research institutions and clinical labs, including population sequencing initiatives (e.g. Genomics England), health systems and hospitals (e.g. University of Pittsburgh Medical Center and Rady Children’s Hospital- San Diego) and national reference laboratories (e.g. LabCorp).

January 10, 2017
Press Release: Omicia Joins Cancer Moonshot’s Blood Profiling Atlas to Advance Circulating Tumor DNA Research
Omicia, Inc., a leading provider of clinical genomic data analysis and reporting tools, was selected to join the Cancer Moonshot’s Blood Profiling Atlas in Cancer (Blood PAC) consortium. In joining Blood PAC, Omicia is demonstrating its commitment to advancing cancer genetics research and extending patients’ lives.

The Blood PAC was formed in October 2016 in alignment with Vice President Joe Biden’s Cancer Moonshot initiative. The scientists in Blood PAC will quickly advance the study of liquid biopsy samples, and develop safe and effective patient blood profiling diagnostic technologies. Blood PAC’s consortium is comprised of about 30 organizations, tasked with creating standardized protocols.

October 19, 2016
Press Release: Rady Children’s Hospital – San Diego Selects Omicia for NICU/PICU Rapid Whole Genome Sequencing Project

Omicia, Inc., a leading provider of clinical genome interpretation and reporting software, announced today that San Diego-based Rady Children’s Institute for Genomic Medicine has chosen the company as their first line genome interpretation partner for the implementation of Rady Children’s rapid genome testing in their neonatal and pediatric intensive care units (NICU/ PICU). Stephen Kingsmore, M.D., D.Sc., President and CEO of Rady Children’s Institute for Genomic Medicine, pioneered the use of rapid genome sequencing to diagnose critically ill infants, and he has recently demonstrated a Guinness World Record-setting time of 26 hours for whole genome sequencing. The goal of Rady Children’s rapid genome testing is to achieve a 24-hour turnaround time for sequencing and analysis, on a large scale. 

Rapid turnaround time is critical to improving outcomes for newborns and infants in intensive care units with urgent, life-threatening issues. To support this turnaround time requirement, Omicia has introduced a new STAT feature in its Opal Clinical software that delivers clinically interpretable information from next-generation sequencing (NGS) data within one hour. This rapid decision support service enables Rady Children’s clinical team to quickly and accurately diagnose patients and develop targeted treatment plans.

October 17, 2016
Press Release: Omicia Delivers Clinical Reports for 100,000 Genomes Project Main Program

Omicia, Inc., a leading provider of clinical genome interpretation and reporting software, announced today that it has delivered more than 500 clinical reports for the 100,000 Genomes Project, and has begun to return clinical reports for the project’s main program. These clinical reports are being delivered to Genomics England, leader of the 100,000 Genomes Project, and to multiple Genomic Medicine Centers in the National Health Service (NHS). One of three genomic interpretation partners selected for the project, Omicia was the first to implement its Opal ClinicalTM software within Genomics England’s secure data center and to deliver clinical reports. These interpretive reports may contain actionable information to enable a better understanding of a patient’s disease and can potentially impact patient treatment.

The 100,000 Genomes Project is a groundbreaking, country sequencing program that focuses on rare diseases and cancer. Samples are being collected from NHS patients with a rare disease and their family members, along with cancer patients. The goal is to apply genomic medicine to improve therapeutic treatments. It is currently the largest genome sequencing project of its kind in the world and through this partnership, Omicia is enabling Genomics England to scale actionable results.

June 08, 2016
Press Release: Omicia Raises $23 Million in Series B Funding

Omicia, Inc., a leading provider of clinical genome interpretation and reporting software, today announced the completion of a $23 million Series B financing round. Several new investors participated in the round, including UPMC Enterprises, Roche Venture Fund, LDV Partners, Ping An Ventures, and a large genomics investor, as well as existing investors ARTIS Ventures, Acadia Woods Partners and Buchanan Investments.

Omicia’s latest financing will be used to fuel acceleration in product development and an expansion in sales, sales support, marketing and operations. In addition, the company plans to extend variations of its flagship OpalTM Clinical platform for use in new geographies and new verticals including life science research, clinical trial support, population health management and consumer applications.

March 09, 2016
Press Release: Omicia Implements ACMG Variant Scoring and Classification Guidelines to Drive Clinical NGS Report Consistency and Throughput

Omicia announces the launch of its new ACMG-scoring module for the Opal Clinical™ interpretation and reporting software platform at the 2016 ACMG Annual Clinical Genetics Meeting. This functionality provides an intuitive interface and workflow for clinical testing labs to systematically assess the disease-causing potential of genetic variants using the evidence-based classification system defined in the 2015 Standards and Guidelines for the Interpretation of Sequence Variants.

March 03, 2016
Press Release: Omicia Announces Appointment of Matt Tindall as Chief Executive Officer

Omicia, leading provider of clinical interpretation software and services for genetic testing labs, announced that Matt Tindall has been appointed CEO and a member of the company’s Board of Directors.

September 30, 2015
Genomics England Press Release: Genomics England announces interpretation partners and expands industry engagement

Genomics England announced today that it has contracted with Omicia to interpret genomic data from the first 8,000 patients participating in the UK’s 100,000 Genomes Project.

September 1, 2015
Press Release: The DNA of a Nation: Nature Magazine Highlights Omicia and the Necessity for Large-Scale Clinical Interpretation for 100,000 Genomes Project

In the recent article “The DNA of a Nation,” Nature magazine highlights the highly-specialized and dedicated clinical interpretation services that Genomics England requires for their 100,000 Genomes Project, which is the first step in bringing genomics to the UK healthcare system. Omicia, the worldwide leader in genome informatics and clinical interpretation, was selected from 28 competing companies to provide interpretation services for the project.

August 27, 2015
Nature: The DNA of a Nation

The United Kingdom aims to sequence 100,000 human genomes by 2017. But screening them for disease-causing variants will require innovative software. For the 100,000 Genomes Project, it will use Omicia’s Opal Clinical genome interpretation software to assess which variants are likely to be causing disease.

August 20, 2015
Press Release: Rare Genomics Institute BeHEARD Rare Disease Science Challenge Winners to Use Omicia’s Clinical NGS Interpretation Software

Rare Genomics Institute (RG) is an international non-profit that that makes cutting edge research technologies of genome sequencing, physicians and scientists around the world accessible to rare disease patients. In partnership with RG, Omicia is delighted to announce the recipients of this year’s BeHEARD Rare Disease Science Challenge, who will receive free access to Omicia’s Opal software in support of their ongoing research.

June 12, 2015

University of Utah Press Release: Genomics England Selects Omicia, University of Utah Technology for 100,000 Genomes Project

Genomics England announce that it will be using technology co-developed in a partnership between Omicia and the University of Utah, and exclusively commercialized through Omicia, to interpret the DNA of Britons as part of the 100,000 Genomes Project, a national effort to hasten creation of diagnostics and treatments that are tailored to a person’s genetic make-up.

June 4, 2015
Press Release: Omicia Wins UK’s 100,000 Genomes Project as Clinical Interpretation Provider

Omicia, the leading clinical genomics company, today announced that it has been selected by Genomics England to provide clinical interpretation services for the 100,000 Genomes Project. For the first phase of the project Illumina will provide sequencing services, while Omicia will provide interpretation and clinical reports.

June 3, 2015
Genomics England: Successful Bidders for Clinical Interpretation Services Announced

Genomics England has selected Omicia to interpret genomic data for the first phase of the UK’s 100,000 Genomes Project.

November 5, 2014
InformationWeek: 8 Innovative Health IT Startups

Omicia is recognized as one of the most innovative startup companies poised to change healthcare.

October 28, 2014
Press Release: Omicia Introduces Phevor to Boost Identification of Disease-Causing Gene Mutations

Omicia today announced it is integrating Phevor™ (Phenotype Driven Variant Ontological Re-ranking tool) into its Opal product offering. Phevor, an algorithm co-developed by the University of Utah and Omicia, accelerates identification of disease-relevant variants in genomic sequences.

October 23, 2014
VentureBeat: Disrupt this: Announcing HealthBeat’s 10 Innovation Showcase finalists

Omicia has been selected as a finalist for the Innovation Showcase at VentureBeat’s HealthBeat 2014 event.  As one of 10 finalists selected from dozens of startups in the digital health space, Omicia will have the opportunity to demonstrate how Opal Clinical will improve patient outcomes by increasing the accuracy, speed, and diagnostic yield of NGS testing.

October 16, 2014
Press Release: Omicia Introduces Opal Clinical, Interpretation Software for NGS Diagnostics

Omicia today announced the commercial availability of Opal Clinical™, the company’s software solution for diagnostic testing organizations.

October 16, 2014
Press Release: Omicia Selected in Genomics England’s Annotation Assessment for Next Stage of 100,000 Genomes Project

Omicia today announced that it has been selected by Genomics England as part of its Annotation Assessment for the 100,000 Genomes Project and will move to the next stage.

October 15, 2014
VentureBeat: Omicia launches ‘Opal Clinical’ genetic interpretation software platform

Omicia is easing the difficult job of interpreting whole-genome sequencing with its new Opal Clinical platform, which is sold as a Software-as-a-Service (SaaS). With Opal, hospitals and diagnostic labs can launch genetic studies faster and interpret results more accurately and quickly.

September 17, 2014
Nature: When Disease Strikes from Nowhere

Disorder-causing mutations are hard to detect — they have to be identified among a host of other, innocuous genetic changes. Omicia’s software tools are profiled as Nature takes a look the tools physicians and researchers use to sift through sequenced genomes in search of such mutations.

June 25, 2014

Press Release: Omicia Taps Renowned Clinical and Genomics Experts for Scientific Advisory Board

Omicia, Inc. today announced that four new world-renowned clinical and genomic scientists will advise the strategic development of Omicia’s clinical diagnostic genome interpretation software, and support the company’s vision of improved patient care through personalized medicine.

June 3, 2014

Press Release: Omicia and LabCorp Collaborate to Offer Comprehensive Genomic Analysis Services for Next-Generation Clinical Trials

Omicia, Inc. today announced that Omicia’s clinical next-generation sequencing (NGS) interpretation software will be used by LabCorp for its clinical trials sequencing services.

May 30, 2014

MD Anderson News Release : New software tool identifies genetic mutations that influence disease risk

Researchers at The University of Texas MD Anderson Cancer Center and other institutions have applied a newly developed software tool, pVAAST, to identify genetic mutations that contribute to a person’s increased risk for developing common, complex diseases, such as cancer. The research is published in the May 2014 edition of the journal Nature Biotechnology.

May 29, 2014

Science Daily: Powerful tool combs family genomes to find shared variations causing disease

A powerful tool called pVAAST that combines linkage analysis with case control association has been developed to help researchers and clinicians identify disease-causing mutations in families faster and more precisely than ever before.

May 9, 2014

GenomeWeb: Omicia, U of Utah Showcase Algorithm for Identifying Disease-Causing Variants in Individual Samples

Omicia’s Martin Reese explains how Phevor–developed in collaboration with the University of Utah and MD Anderson Cancer Center — offers a more automated means of selecting the gene variants that likely play the most pertinent roles in a particular patient’s disease phenotype.

May 7, 2014

Press Release: Dr. Paul Billings Joins Omicia as Chief Medical Officer

Omicia announced the appointment of Paul Billings, M.D., Ph.D., as Chief Medical Officer. Dr. Billings joins Omicia as genomics expands from the research lab to become a valuable clinical diagnostic tool.

April 22, 2014

ScienceDaily: Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses

Phevor works by using algorithms that combine the probabilities of gene mutations being involved in a disease with databases of phenotypes, or the physical manifestation of a disease, and information on gene functions. By combining those factors, Phevor identifies an undiagnosed disease or the most likely candidate gene mutation for causing a disease.

April 22, 2014

PR Newswire: University of Utah’s New Phevor Software Identifies Disease-Causing Gene Mutations in Three Undiagnosed Children

Omicia and colleagues at the USTAR Center for Genetic Discovery and MD Anderson Cancer Center report that they have successfully identified diseases with unknown gene mutations in three separate cases using the collaboratively-developed Phevor (Phenotype Driven Variant Ontological Re-ranking tool).

March 19, 2014

Science & Enterprise: Genetics Group, Analytics Firm Collaborate on Diagnostics

A genetics research center at University of Utah in Salt Lake City and Omicia Inc., a genomic analytics company in Oakland, California are developing systems to make genomic analysis a routine medical diagnostic procedure.

March 18, 2014

Mendelspod: Bioinformatics Pioneer, Martin Reese, on Scaling Up Human Genome Interpretation

Martin Reese, co-founder and President of Omicia, Inc., explains how making tools to simplify genetic analysis reports will increase the clinical applications of human genome sequencing over the next 3-5 years.

March 18, 2014

ScienceDaily: From DNA to Diagnosis: Integrating Genome Data into Patient Care

The USTAR Center for Genetic Discovery is partnering with California-based Omicia, Inc., to make analyzing a patient’s genome as routine as performing a blood test.

Jan. 8, 2014

GenomeWeb: Omicia to Use New Funds to Develop Diagnostic Pipeline for Opal, Improve Interpretation Abilities

Omicia plans to use the proceeds from a recent $6.8 million Series A financing to continue developing an informatics workflow that would help diagnostic laboratories develop and launch genomics-based tests.

Jan. 7, 2014

VentureBeat: Omicia hopes to boil down genomic big data into more useful information, raises $6.8M

Omicia has picked up a $6.8 million Series A led by Artis Ventures. Other investors include Buchanan Investments and Bay City Capital.

Jan. 7, 2014

Press Release: Omicia Raises $6.8M to Accelerate Whole Genome Interpretation

Omicia, Inc., an analytical genome interpretation company, announced today it has closed $6.8 million of Series A financing to expand its marketing reach and further optimize its big data genomics offerings.

Dec. 6, 2013

GenomeWeb: University of Utah Licenses Omicia’s Opal for Genomic Interpretation

Omicia and the University of Utah said this week that they have signed a two-year licensing agreement that allows researchers involved in the Utah Genome Project use Opal, Omicia’s platform for analyzing genomics in research and clinical applications, to analyze disease-causing variants.

Dec. 4, 2013

Press Release: Omicia and University of Utah Health Sciences sign agreement to use Opal platform to analyze and interpret personal genomes for the clinic

Under a two-year licensing agreement with Omicia, the University of Utah’s Utah Genome Project will use and advance Opal, the company’s whole genome analysis platform for research and clinical applications.

Oct. 4, 2013

GenomeWeb: Researchers Detail Use of Precision Medicine in Mental Illness Case

A team of clinicians and researchers used whole-genome sequencing to uncover variants possibly linked to a patient’s obsessive-compulsive disorder.

Sept. 5, 2013

New Scientist: Our Genomic Future

Genome sequencing is starting to deliver a medical revolution for families with rare diseases. The benefits may one day come to us all.

May. 16, 2013

University of Utah Health Care: University of Utah Health Sciences Launches Genome Board to Treat Undiagnosed Patients

The University of Utah Health Sciences has formally launched a Genome Board—an interdisciplinary, clinical rounds system that processes complex genetic information into actionable clinical knowledge. Included in the analysis procedure is a software tool called Opal, developed by Omicia, Inc.

April 16, 2013

Press Release: Real Time Genomics and Omicia Partner on a Platform for Integrated Genomic Analysis for Childhood Disease

Real Time Genomics, Inc., and Omicia, Inc. today announced a commercial partnership to deliver genome analytics for the clinical interpretation of genomes for childhood diseases.

March 12, 2013

Press Release: Spiral Genetics Closes $3 Million in Funding Led by DFJ and Announces Partnership with Omicia

Spiral Genetics announced its partnership with Omicia, a developer of scalable and fully integrated informatics systems specifically designed to interpret human genome sequences for research and clinical applications.

January 2, 2013

Business Wire: Genome Interpretation Company Omicia Appoints Mike Aicher as CEO

Omicia announced the appointment of former National Genetics Institute CEO Mike Aicher as Chief Executive Officer and member of the company’s Board of Directors.

May 10, 2012

Business Wire: Omicia Provides Early Access to Powerful Solution for Individual Genome Interpretation

Omicia, Inc. announced today that it has initiated an early access program for its individual genome interpretation product. Through this product, Omicia will enable users to prioritize and identify disease genes and their variants using an intuitive and interactive web-based application environment.

April 25, 2012

Bio-IT World: Bio-IT World Announces Winners of 2012 Best Practice Awards

Omicia and University of Utah win the 2012 Grand Prize in Personalized and Translational Medicine at the Bio-IT Best Practices Awards competition.

February 17, 2012

San Francisco Business Times: Omicia Frees VAAST Data to Find Vital Gene Variants

VAAST — the Variant Annotation, Analysis and Selection Tool — was developed by Omicia Inc. and the University of Utah to allow medical researchers to rapidly identify gene variants.

November 1, 2011

GenomeWeb: Next-Gen Tools Have Near-Term Applications in the Clinic, Companies Say

At the International Congress of Human Genetics meeting held last month in Montreal, Quebec, representatives from Omicia, Inc. discussed near-term applications of their tools, including how they may be used in the clinic.

November 2011

Future Medicine: Personal Account of the Discovery of a New Disease Using Next-Generation Sequencing

A data interpretation bottleneck has limited the utility of personal genome information for medical diagnosis and preventive care. VAAST, developed by Omicia, Inc. and the University of Utah, is a new algorithm to assist in overcoming this bottleneck.

October 11, 2011

Nature Medicine: Businesses Ready Whole-Genome Analysis Services for Researchers

The cost of sequencing an individual’s entire genome has fallen precipitously over the past five years, from around $100 million for the first personal genome to under $5,000 today when sequencing services are purchased in bulk.

July 1, 2011

BioInform: Omicia, U of Utah Researchers Use Integrated Approach to Improve Disease-Gene Searching

Scientists from the University of Utah and Omicia, Inc. have developed a software package that requires a relatively small sample size to functionally interpret whole-genome sequence data which they claim is more accurate than existing methods.

June 30, 2011

Forbes: A Tragic Case And A Genomic Hope

Omicia’s VAAST algorithm allowed Gholson J. Lyon, a psychiatrist and genetics researcher at the Children’s Hospital of Philadelphia, to find the defective gene that has caused five children in one family to die from a mysterious disease.

June 29, 2011

GenomeWeb: Following Proof of Concept for Algorithm, Omicia Preps Launch of Clinical Genome Analysis Platform

Following a proof of principle for its disease-gene finding algorithm, genome interpretation startup Omicia plans to launch a platform for the clinical analysis of human genomes later this year.

June 28, 2011

Genetic Engineering News: A New Tool for Personal Genomics

Dr. Gholson Lyon explores the use of the VAAST software system and explains the advantages of the VAAST technique versus other methods and talks about additional research that his team has planned to make VAAST even more effective for personal genomics applications.

June 24, 2011

The Salt Lake Tribune: Utah Researchers Find Mutation That Kills Baby Boys

Using software developed by Omicia and the University of Utah, geneticists have identified the mutation that causes a mysterious, previously unnamed affliction that has killed several baby boys born to an Ogden, Utah family.

June 24, 2011

Smart Planet: Software Used to Identify Rare Genetic Disorder; Could Impact Diagnosis

Researchers at the University of Utah and informatics company Omicia, Inc., are using a software program called the Variant Annotation, Analysis & Search Tool (VAAST) to find the root cause of a disease caused by a rare genetic disorder. After sequencing two families, the scientists used the program to identify a previously unknown syndrome in an individual.

June 23, 2011

Bio-IT World: VAAST Potential for New Genome Mutation Hunting Software

Scientists at the University of Utah and a Bay Area software company, Omicia, have released details of a powerful computational tool for identifying disease-causing mutations by individual genome sequencing. Researchers have used the software to rapidly screen genomic data to identify a deleterious mutation in a fatal X-linked disorder.

June 23, 2011

Nature: Software pinpoints cause of mystery genetic disorder

The VAAST genome analysis tools speedily tracks down previously unknown mutation.

June 23, 2011

American Association for the Advancement of Science EurekAlert!: Next-Generation Gene Sequencing Brings Personal Genomics Closer, IDs Mutation in New Syndrome

Harnessing the new generation of rapid, highly accurate gene-sequencing techniques, a research team has identified the disease-causing mutation in a newly characterized rare genetic disease, by analyzing DNA from just a few individuals.

June 23, 2011

American Association for the Advancement of Science EurekAlert!: Computational Software Provides Rapid Identification of Disease-Causing Gene Variations

Scientists from the University of Utah and Omicia, Inc., a privately held company developing tools to interpret personal genome sequences, today announced the publication in Genome Research of a new software tool called VAAST, the Variant Annotation, Analysis and Selection Tool, a probabilistic disease-causing mutation finder for individual human genomes.

May 13, 2011

Forbes: DNA Sequencing: Beating Moore’s Law Since January 2008

At the Cold Spring Harbor Laboratory Biology of Genomes meeting, researchers presented a new computer program called VAAST that can automate finding disease genes.

April 1, 2011

Bio-IT World: New Study Reveals 1 Million Human Genome Sequence Errors Across Two NGS Platforms

Omicia and collaborators at the University of Utah are mining personal genome sequences, identifying all known alleles associated with ill health, and then relating that information to known genetic variants in an easy manner for rapid clinical reports.

September 28, 2010

Bio-IT World: The $1,000,000 Genome Interpretation

Omicia is taking genome data and extracting clinical meaning, focusing on DNA variation, rather than gene expression or pathways. Omicia is also developing algorithms to predict the effect of protein-coding variants to better understand which mutations are medically relevant.

July 13, 2010

GenomeWeb: Omicia Readies Technology to Interpret Human Genomes for Clinical Projects

Amid a market that noisily trumpets every advance in human genome sequencing technology, informatics firm Omicia has been quietly working on ways to interpret genomic data by linking genetic variants to disease.

Upcoming Events

February 19-25, 2017
Molecular Medicine Tri-Con 2017
Moscone North Convention Center, San Francisco
Martin Reese, Ph.D. speaking
Tue. Feb. 21, 3:40-3:55PM
Track: Personalized Diagnostics- What Can NGS Bring to Medicine
Increasing Diagnostic Yield in Whole Genome Interpretation Using Omicia’s Opal Clinical Platform

February 19-23, 2017
HIMMS 17 Health IT Conference for 2017
Orlando, Florida
For Meetings, contact: